What Antux Treats: Main Uses and Benefits

Antux is used for the symptomatic management of dry cough (non-productive, disturbing cough). It is generally indicated in situations involving certain distressing symptoms related to inflammatory or irritative states in the airways.

It helps address symptom clusters that may become intense or disruptive, commonly associated with conditions presenting with acute episodes such as acute bronchitis, upper respiratory tract infections, and persistent chronic cough syndromes. This supportive relief contributes to easing the overall symptom load and helps improve day-to-day comfort.

Antux is used to address symptoms that interfere with daily functioning, particularly when a persistent cough affects sleep quality (nocturnal awakenings). It supports the patient during difficult episodes by easing distress and provides supportive relief when symptoms interfere with routine activities.

“The medication is used for easing symptoms that are linked to the non-productive cough pattern.”

Quick Fact: Relief for Irritative Cough
Antux may assist with easing the frequency and intensity of a dry, hacking cough across adult and relevant pediatric patient groups.

Who Can and Cannot Use Antux?

This section defines population eligibility for Antux (Levodropropizine) based strictly on official governmental regulatory documents, outlining which groups are permitted, restricted, or prohibited from using the medicine.

---

Populations Prohibited from Use (Contraindicated)

Antux is contraindicated and must not be used in the following populations, as stated in regulatory labeling:

• Age: Children under 2 years of age.
• Physiological States: Women who are pregnant or breastfeeding (lactating).
• Hypersensitivity: Patients with known hypersensitivity to the active substance or excipients.
• Respiratory Conditions: Individuals with bronchorrhea (excessive mucus discharge) or severely reduced mucociliary function.
• Organ Failure: Patients with severe hepatic (liver) failure.

---

Populations Requiring Caution or Restriction

Use of Antux is conditional or requires caution in specific patient groups:

• Older Adults: Used with caution due to potential changes in pharmacokinetics and increased sensitivity.
• Renal Impairment: Requires caution in patients with severe renal failure (creatinine clearance below 35 ml/min).
• Comorbidities: Diabetic patients must account for the sucrose content in the oral solution.

Antux is permitted for use in adults and children aged 2 years and older who do not have any of the listed contraindications.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Levodropropizine (Antux) as stated in government regulatory labeling.

---

Pharmacodynamic and Drug–Drug Interactions

Official labeling requires careful administration when the medicine is used concurrently with sedative agents in sensitive individuals. This caution is based on the theoretical potential for additive depressant effects.

However, clinical trials observed no interaction with benzodiazepines, and animal studies confirmed no potentiation of the central effects of substances like alcohol, phenytoin, or imipramine.

Clinical studies also confirmed the absence of interaction with commonly co-administered bronchopulmonary medications, including beta-2-agonists, methylxanthines, corticosteroids, antibiotics, and mucoregulators.

---

Administration and Clearance Constraints

Constraint Category	Official Regulatory Statement
Timing Rule (Syrup)	The syrup formulation should be taken away from meals due to a lack of data on food's influence on absorption.
Excipient Restriction	The presence of sucrose in the syrup results in a contraindication for patients with specific rare hereditary problems like fructose intolerance.
Clearance-Based Caution	The medicine is contraindicated in individuals with severe hepatic disorders and requires caution in patients with serious renal insufficiency (creatinine clearance below 35 mL/min).

No specific metabolic (CYP) or transporter-mediated interactions are documented in the official regulatory texts.

Peripheral Action: Targeting Airway Sensory Nerves

Antux initiates its effect by acting as an inhibitor on voltage-gated sodium channels (NaV channels) located on the membranes of peripheral afferent nerve fibers (C-fibers) in the respiratory mucosa. This specific interaction stabilizes the neuronal membranes, thereby decreasing the excitability of these sensory receptors and preventing their depolarization. This action is primarily localized to the peripheral nervous system, limiting the conduction of electrical signals along the afferent pathway.

---

Molecular Blockade and Reflex Threshold Modulation

This mechanism is defined by the molecular blockade that directly lowers the firing rate of the airway sensory nerves. The resultant suppression of afferent nerve activity effectively elevates the reflex threshold, meaning a significantly stronger sensory input is required to activate the central reflex center. This physiological modulation leads to a systemic physiological adjustment of reflex sensitivity within the respiratory system.

How Antux (Levodropropizine) is Used: Administration Guidelines

This section describes the general principles for the administration of Antux (Levodropropizine).

---

Route and Timing

Antux is for oral use and is commonly available as an oral solution or syrup. The medication should ideally be taken away from meals (on an empty stomach), as the effect of food on its absorption is not fully determined.

---

Standard Dosing Regimens

The following intervals and limits are typically applied for administration. The medication is generally taken up to three times per day, with an interval of at least 6 hours between each administration.

Population	Standard Dose	Maximum Daily Dose	Frequency
Adults and Adolescents (12 years)	60 mg per dose (e.g., 10 mL syrup)	180 mg	Up to 3 times daily

---

Administration for Specific Populations

• Children (2 to 12 years): Dosing is calculated based on body weight, generally ranging from 1 mg/kg to 2 mg/kg per dose, up to three times daily. A calibrated dosing device must be used to ensure accurate measurement of the prescribed volume.
• Older Adults (Geriatric): Caution is recommended due to potential changes in drug handling linked to age, although explicit dose reduction is not always specified.
• Duration of Use: Treatment is intended for a brief period only. If the cough persists beyond a specific duration (commonly 7 to 14 days), use of the medication should be reassessed.

Research Evidence / Overview of Studies for Antux (Levodropropizine)

---

Evidence for Use in Acute Non-Productive (Dry) Cough

Research exploring Antux has focused primarily on its application in studies examining patient-reported experiences of a disruptive, dry cough, such as those that can occur with upper respiratory tract infections (URTIs) and acute bronchitis. The evidence base here consists of many short-term Randomized Controlled Trials (RCTs), where people were randomly assigned to receive either Antux, a placebo, or another medicine. These trials monitored specific outcomes, such as how often a person coughed and the severity of the cough, which are relevant in research exploring how symptoms change over time.

Findings described patterns where patient-reported outcomes describing perceived discomfort were often measured as lower in the groups receiving Antux. Studies also reported that the recorded number of nocturnal awakenings attributed to cough was often documented as being less frequent over the defined observation interval. However, the follow-up durations were typically short (less than one week), concentrating the evidence on the acute phase of illness.

---

Evidence for Use in Chronic Cough and Specific Diseases

Antux was studied for managing cough that is persistent, often referred to as chronic non-productive cough. Research here includes a mix of controlled trials and observational settings that examined daily-life functioning in conditions where symptoms may vary in intensity. Findings described patterns where cough severity scores were measured as being lower over intermediate follow-up periods, which typically lasted a few weeks. The evidence base for chronic cough is often derived from a smaller and more heterogeneous set of studies compared to the acute setting.

For certain specific, less common clinical situations, such as managing non-productive cough associated with lung cancer, the evidence is limited. Small-scale trials have explored Antux in these specific cohorts, but the sample sizes were modest, meaning the results apply only to the populations studied.

---

Research Gaps and Areas of Uncertainty

Scientific reviews and regulatory assessments note several areas where the evidence is limited or where additional research is needed. One key limitation is the heavy reliance on patient-reported outcomes describing perceived discomfort rather than objective physiological measures of the cough reflex. Additionally, while the evidence is substantial for acute cough, the evidence quality varies across studies for chronic cough, and certainty remains low regarding sustained effects or benefits in very specific, complex subgroups. Long-term effects are not fully established.

Key Studies & References

1. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies
2. A Newer Approach in the Management of Cough: A Review on Levodropropizine
3. Levodropropizine: A promising peripherally acting antitussive agent - Clinical and Regulatory Context

Common questions about Antux (FAQ)

---

Q: Does this medication make you sleepy?

Official product information states that this medication may cause dizziness and somnolence (a medical term for sleepiness). These effects are listed as among the most common side effects reported during clinical trials. Awareness of these potential effects is important for patients using Antux.

---

Q: Is it safe for long-term use?

Regulatory documents list potential side effects that have been reported during both initial and chronic treatment with the medication. For example, conditions like Angioedema (a type of swelling) have been noted as risks. Official information also notes that adverse reactions may occur if the medication is abruptly or rapidly discontinued, which is a common caution for medications of this class.

---

Q: Can children 2 years old use it?

According to the official prescribing information, this medication is approved as a supplemental treatment for a specific type of seizure in pediatric patients who are 1 month of age and older. However, it is important to note that the medication is not approved for other indications, such as nerve pain or fibromyalgia, in patients under 18 years old. The indication for use is dependent on the specific medical condition being addressed and the patient's age, according to the official label.

How to Store and Dispose of Antux? (Levodropropizine)

Official regulatory guidelines define specific conditions for storing and disposing of Antux to maintain its quality.

---

Storage Conditions

Requirement	Instruction
Temperature	Store at temperatures not exceeding 30 C (86 F).
Protection	Protect from light and store in the original container, kept tightly closed.
Child Safety	Keep out of reach of children.

Stability and Disposal

The oral solution formulation must be discarded after 1 month of first opening to ensure stability.

Disposal of any unused or expired product must be executed in accordance with local and national pharmaceutical waste regulations. Medicines should not be disposed of via wastewater or household trash unless local authorities explicitly permit this method.